Osel Sees Immunotherapy-Like Trajectory For Oncology Microbiome Candidate
Executive Summary
Depending on financing, the company could start a Phase III trial of CBM588 as early as this year, but it’s looking to develop the microbiome therapeutic for a potentially broad array of cancers.
You may also be interested in...
Early Success For 4D Pharma’s Microbiome Plus Keytruda Combination
After years of halting progress in its microbiome-based pipeline, 4D Pharma has produced promising early data from its cancer immunotherapy combination.
Amylyx’s Relyvrio Could See Fast Sales Growth, But Also Spark Pricing Debate
The FDA gave full approval based on a Phase II study, without the need for Phase III confirmatory data, for Amylyx’s ALS drug Relyvrio but the $158,000 WAC could spark a debate over pricing.
Biohaven’s Non-Migraine Portfolio Takes Another Hit As Verdiperstat Fails In ALS
Pfizer is buying Biohaven's migraine portfolio, but the rest of the pipeline is poised to be spun out and there have been two development setbacks. Despite verdiperstat's failure in ALS, the field had a same-day win with Amylyx's Relyvrio approval.